Madhav Dhodapkar

Summary

Affiliation: Yale University
Country: USA

Publications

  1. pmc Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?
    Madhav V Dhodapkar
    Yale University School of Medicine, 333 Cedar Street, Box 208028, New Haven, CT 06510, USA
    Cancer Prev Res (Phila) 6:173-6. 2013
  2. pmc Vaccines targeting cancer stem cells: are they within reach?
    Madhav V Dhodapkar
    Departments of Medicine, Immunobiology and Pediatrics, Yale University, New Haven, CT, USA
    Cancer J 17:397-402. 2011
  3. pmc Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Clin Immunol 140:160-6. 2011
  4. pmc Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Cancer Immunol Immunother 60:413-8. 2011
  5. pmc Immunity to stemness genes in human cancer
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Curr Opin Immunol 22:245-50. 2010
  6. pmc Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges
    Madhav V Dhodapkar
    Hematology Section, Yale University School of Medicine, New Haven, CT 06510, USA
    Front Biosci (Landmark Ed) 14:796-807. 2009
  7. pmc Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003
    Madhav V Dhodapkar
    Section of Hematology and Yale Cancer Center, Yale University, New Haven, CT 06510, USA
    Blood 113:793-6. 2009
  8. pmc Role of chaperones and FcgammaR in immunogenic death
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT, USA
    Curr Opin Immunol 20:512-7. 2008
  9. pmc Natural immunity to pluripotency antigen OCT4 in humans
    Kavita M Dhodapkar
    Department of Pediatrics, Yale University, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 107:8718-23. 2010
  10. pmc Harnessing CD1d-restricted T cells toward antitumor immunity in humans
    Natalia Neparidze
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Ann N Y Acad Sci 1174:61-7. 2009

Research Grants

  1. Anti-Tumor immunity in myeloma
    Madhav Dhodapkar; Fiscal Year: 2007
  2. Targeting myeloma via dendritic cells
    Madhav Dhodapkar; Fiscal Year: 2009
  3. Immunity to stem cell antigens in preneoplastic gammopathy
    Madhav Dhodapkar; Fiscal Year: 2009
  4. Immunity to stem cell antigens in preneoplastic gammopathy
    Madhav V Dhodapkar; Fiscal Year: 2010
  5. Immunity to stem cell antigens in preneoplastic gammopathy
    Madhav Dhodapkar; Fiscal Year: 2009

Collaborators

  • Zihai Li
  • Antje Hoering
  • Bart Barlogie
  • Morie A Gertz
  • Natalia Neparidze
  • Kavita M Dhodapkar
  • Carole L Berger
  • Stefan Turkula
  • Henry Zebroski
  • Darren Feldman
  • Roxana Pickering
  • Soroosh Radfar
  • Phillip Matthews
  • Douglas Hanlon
  • Vivian Lombillo
  • Jill Crouch
  • Nianci Wang
  • Daniel Kanada
  • Richard Edelson
  • Gregory Howe
  • Paul El-Fishawy
  • Inger Christensen

Detail Information

Publications12

  1. pmc Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?
    Madhav V Dhodapkar
    Yale University School of Medicine, 333 Cedar Street, Box 208028, New Haven, CT 06510, USA
    Cancer Prev Res (Phila) 6:173-6. 2013
    ..We try to make the case to consider individualized approaches based on the genetic make-up of tumor cells and properties of the host response. Such strategies may be needed to optimally position the immune system to prevent cancers...
  2. pmc Vaccines targeting cancer stem cells: are they within reach?
    Madhav V Dhodapkar
    Departments of Medicine, Immunobiology and Pediatrics, Yale University, New Haven, CT, USA
    Cancer J 17:397-402. 2011
    ..Immunologic approaches targeting stemness-associated pathways in cancer may provide an important strategy for the prevention of diverse cancers, including those occurring in the context of regenerative therapies...
  3. pmc Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Clin Immunol 140:160-6. 2011
    ..These results have set the stage for ongoing studies combining NKT activation with immune-modulatory drugs. Lessons learnt from these studies may inform the optimal application of human NKT based therapies in other settings as well...
  4. pmc Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Cancer Immunol Immunother 60:413-8. 2011
    ..Immunologic targeting of pathways associated with stemness has implications for both immune regulation of tumor growth as well as emerging regenerative therapies with embryonal stem cells...
  5. pmc Immunity to stemness genes in human cancer
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Curr Opin Immunol 22:245-50. 2010
    ..Immunologic targeting of pathways associated with stemness has implications for both immune regulation of tumor growth as well as regenerative therapies with embryonal stem cells...
  6. pmc Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges
    Madhav V Dhodapkar
    Hematology Section, Yale University School of Medicine, New Haven, CT 06510, USA
    Front Biosci (Landmark Ed) 14:796-807. 2009
    ..However several challenges need to be overcome in order to effectively harness the properties of these cells in the clinic...
  7. pmc Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003
    Madhav V Dhodapkar
    Section of Hematology and Yale Cancer Center, Yale University, New Haven, CT 06510, USA
    Blood 113:793-6. 2009
    ..001). These data provide novel insights into factors predicting long-term outcome in WM. This trial has been registered with www.cancer.gov under ID 4852904...
  8. pmc Role of chaperones and FcgammaR in immunogenic death
    Madhav V Dhodapkar
    Section of Hematology, Yale University, New Haven, CT, USA
    Curr Opin Immunol 20:512-7. 2008
    ..Understanding both these pathways of immunogenic cell death may yield novel approaches to regulate immunity...
  9. pmc Natural immunity to pluripotency antigen OCT4 in humans
    Kavita M Dhodapkar
    Department of Pediatrics, Yale University, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 107:8718-23. 2010
    ..Harnessing natural immunity to this antigen may allow immune-based targeting of pluripotency-related pathways for prevention of cancers, including those in the setting of ES/IPS-based therapies...
  10. pmc Harnessing CD1d-restricted T cells toward antitumor immunity in humans
    Natalia Neparidze
    Section of Hematology, Yale University, New Haven, CT 06510, USA
    Ann N Y Acad Sci 1174:61-7. 2009
    ..Harnessing CD1d-restricted T cells in cancer may depend on regulating the balance between type I and II NKT cells and holds promise as a broad strategy for immune therapy of several cancers...
  11. ncbi request reprint The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells
    Carole L Berger
    Yale University, School of Medicine, Department of Dermatology and Laboratory Medicine, New Haven, CT 06510, USA
    Blood 99:2929-39. 2002
    ..In addition, the culture of CTCL cells will permit evaluation of therapies in vitro before clinical intervention, thereby improving safety and efficacy...
  12. pmc Waldenstrom's macroglobulinemia: Recent advances in biology and therapy
    Natalia Neparidze
    Yale University, New Haven, CT 06510, USA
    Clin Adv Hematol Oncol 7:677-81, 687-90. 2009
    ..This report provides an update on recent advances in biology and treatment of this disease...

Research Grants11

  1. Anti-Tumor immunity in myeloma
    Madhav Dhodapkar; Fiscal Year: 2007
    ..abstract_text> ..
  2. Targeting myeloma via dendritic cells
    Madhav Dhodapkar; Fiscal Year: 2009
    ..abstract_text> ..
  3. Immunity to stem cell antigens in preneoplastic gammopathy
    Madhav Dhodapkar; Fiscal Year: 2009
    ..Harnessing such responses may be important for prevention of cancer, such as myeloma. ..
  4. Immunity to stem cell antigens in preneoplastic gammopathy
    Madhav V Dhodapkar; Fiscal Year: 2010
    ..Harnessing such responses may be important for prevention of cancer, such as myeloma. ..
  5. Immunity to stem cell antigens in preneoplastic gammopathy
    Madhav Dhodapkar; Fiscal Year: 2009
    ..Harnessing such responses may be important for prevention of cancer, such as myeloma. ..